JP2022504638A5 - - Google Patents
Info
- Publication number
- JP2022504638A5 JP2022504638A5 JP2021519747A JP2021519747A JP2022504638A5 JP 2022504638 A5 JP2022504638 A5 JP 2022504638A5 JP 2021519747 A JP2021519747 A JP 2021519747A JP 2021519747 A JP2021519747 A JP 2021519747A JP 2022504638 A5 JP2022504638 A5 JP 2022504638A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- nephropathy
- kidney
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022209518A JP2023040106A (ja) | 2018-10-11 | 2022-12-27 | 統合的ストレス経路のプロドラッグ調節剤 |
| JP2025027546A JP2025081607A (ja) | 2018-10-11 | 2025-02-25 | 統合的ストレス経路のプロドラッグ調節剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744293P | 2018-10-11 | 2018-10-11 | |
| US62/744,293 | 2018-10-11 | ||
| PCT/US2019/055850 WO2020077217A1 (en) | 2018-10-11 | 2019-10-11 | Prodrug modulators of the integrated stress pathway |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209518A Division JP2023040106A (ja) | 2018-10-11 | 2022-12-27 | 統合的ストレス経路のプロドラッグ調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022504638A JP2022504638A (ja) | 2022-01-13 |
| JP2022504638A5 true JP2022504638A5 (https=) | 2022-10-19 |
| JP7203964B2 JP7203964B2 (ja) | 2023-01-13 |
Family
ID=68387427
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519747A Active JP7203964B2 (ja) | 2018-10-11 | 2019-10-11 | 統合的ストレス経路のプロドラッグ調節剤 |
| JP2022209518A Pending JP2023040106A (ja) | 2018-10-11 | 2022-12-27 | 統合的ストレス経路のプロドラッグ調節剤 |
| JP2025027546A Pending JP2025081607A (ja) | 2018-10-11 | 2025-02-25 | 統合的ストレス経路のプロドラッグ調節剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022209518A Pending JP2023040106A (ja) | 2018-10-11 | 2022-12-27 | 統合的ストレス経路のプロドラッグ調節剤 |
| JP2025027546A Pending JP2025081607A (ja) | 2018-10-11 | 2025-02-25 | 統合的ストレス経路のプロドラッグ調節剤 |
Country Status (35)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| TWI877863B (zh) * | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MA54953A (fr) | 2019-02-13 | 2021-12-22 | Denali Therapeutics Inc | Composés, compositions et procédés |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| MX2023004623A (es) | 2020-10-22 | 2023-05-12 | Evotec Int Gmbh | Moduladores de la via integrada de respuesta al estres. |
| JP2023546224A (ja) | 2020-10-22 | 2023-11-01 | エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 統合ストレス応答経路のモジュレーター |
| US20230391763A1 (en) | 2020-10-22 | 2023-12-07 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| US12416736B2 (en) | 2020-11-13 | 2025-09-16 | National University Corporation Shizuoka University | Radiographic device |
| AU2021407138A1 (en) * | 2020-12-25 | 2023-06-29 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Use of nk1 antagonist prodrug compound in combination with 5-ht3 receptor antagonist |
| EP4396305B1 (en) | 2021-09-01 | 2026-05-06 | EmpathBio, Inc. | Synthesis of mdma or its optically active (r)- or (s)-mdma isomers |
| US12492178B2 (en) | 2021-09-01 | 2025-12-09 | Empathbio, Inc. | Stable polymorph of R-MDMA HCl |
| WO2023056102A1 (en) | 2021-10-01 | 2023-04-06 | ATAI Life Sciences AG | Novel prodrugs of mdma, mda, and derivatives thereof |
| US11912680B2 (en) | 2021-12-28 | 2024-02-27 | Empathbio, Inc. | Nitric oxide releasing prodrugs of MDA and MDMA |
| WO2025230528A1 (en) * | 2024-05-01 | 2025-11-06 | Calico Life Sciences Llc | Methods of treating amyotrophic lateral sclerosis |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162A (en) | 1837-04-17 | Island | ||
| US5212A (en) | 1847-07-31 | Richard m | ||
| GB1026506A (en) | 1962-10-17 | 1966-04-20 | Du Pont | Bicyclodiamines and preparation thereof |
| US3264351A (en) | 1964-07-08 | 1966-08-02 | American Home Prod | 1, 4-diaminobicyclo [2.2.2] octanes |
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JPH02215779A (ja) | 1989-02-14 | 1990-08-28 | Kuraray Co Ltd | カルボン酸アミド誘導体類及びその医薬用途 |
| US5047406A (en) | 1989-12-06 | 1991-09-10 | Warner-Lambert Co. | Substituted cyclohexanols as central nervous system agents |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| AU675730B2 (en) | 1993-07-16 | 1997-02-13 | Merck & Co., Inc. | Substituted piperazinylcamphor derivatives as oxytocin antagonists |
| US7091380B2 (en) | 2002-02-08 | 2006-08-15 | Merck & Co., Inc. | N-biphenylmethyl aminocycloalkanecarboxamide derivatives |
| TWI259079B (en) | 2002-02-08 | 2006-08-01 | Merck & Co Inc | N-biphenyl(substituted methyl)aminocycloalkanecarboxamide derivatives |
| EP1571146A4 (en) | 2002-12-10 | 2010-09-01 | Ono Pharmaceutical Co | NITROGENIC HETEROCYCLIC COMPOUNDS AND THEIR MEDICAL USE |
| JO2397B1 (en) | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| WO2004082606A2 (en) * | 2003-03-13 | 2004-09-30 | Synta Pharmaceuticals Corp. | Fused pyrrole compounds |
| EP1706384A1 (en) | 2004-01-07 | 2006-10-04 | AstraZeneca AB | Therapeutic agents i |
| EP1717225A4 (en) | 2004-02-18 | 2009-10-21 | Kyorin Seiyaku Kk | BICYCLIC AMID DERIVATIVES |
| CN101142172A (zh) | 2005-01-05 | 2008-03-12 | 艾博特公司 | 11-β-羟甾类脱氢酶1型酶的抑制剂 |
| JP2009504624A (ja) | 2005-08-08 | 2009-02-05 | アージェンタ ディスカバリー リミテッド | ビシクロ［２．２．１］ヘプタ−７−イルアミン誘導体およびその使用 |
| CA2672815A1 (en) | 2006-12-15 | 2008-06-26 | Pfizer Products Inc. | Benzimidazole derivatives for use in treating abnormal cell growth |
| KR20110073500A (ko) | 2008-09-08 | 2011-06-29 | 메르크 파텐트 게엠베하 | 오로라 키나아제 억제제로서 마크로사이클릭 피리미딘 |
| HRP20090186A2 (hr) | 2009-03-31 | 2010-10-31 | Institut Ruđer Bošković | Adamantanski bisureidni derivati, metoda priprave i primjena u detekciji aniona |
| WO2011087758A1 (en) | 2009-12-22 | 2011-07-21 | H. Lundbeck A/S | Adamantyl amide derivatives and uses of same |
| AR084457A1 (es) | 2010-12-22 | 2013-05-15 | Lundbeck & Co As H | Derivados de biciclo[3,2,1]octilamida |
| WO2013161980A1 (ja) | 2012-04-27 | 2013-10-31 | 東レ株式会社 | シクロヘキサンジアミド誘導体及びその医薬用途 |
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| US9580459B2 (en) | 2013-04-26 | 2017-02-28 | Metselex, Inc. | Water-soluble ursodeoxycholic acid prodrugs |
| US20160318856A1 (en) | 2013-09-11 | 2016-11-03 | The Brigham And Women's Hospital, Inc. | Substituted Urea eIF2alpha Kinase Activators |
| CN110229142A (zh) | 2014-04-04 | 2019-09-13 | 希洛斯医药品股份有限公司 | 细胞周期蛋白依赖性激酶7(cdk7)的抑制剂 |
| US20150362847A1 (en) | 2014-06-13 | 2015-12-17 | Canon Kabushiki Kaisha | Electrophotographic photosensitive member, process cartridge and electrophotographic apparatus |
| WO2016058544A1 (en) | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| BR112017023764A2 (pt) | 2015-05-05 | 2018-07-31 | Bayer Pharma AG | derivados de ciclohexano substituído por amido |
| WO2017040606A1 (en) | 2015-08-31 | 2017-03-09 | Proteostasis Therapeutics, Inc. | Isoxazole derivatives for use in the treatment of pulmonary diseases and disorders |
| TW201722958A (zh) | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產（第二）有限公司 | 化學化合物 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| CA3026982A1 (en) | 2016-06-08 | 2017-12-14 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN109641910A (zh) | 2016-06-24 | 2019-04-16 | 梅尔莎纳医疗公司 | 吡咯并苯二氮*及其缀合物 |
| CN106349130B (zh) | 2016-08-25 | 2018-01-23 | 潍坊大有生物化工有限公司 | 一种新的氟苯尼考的合成方法 |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| CN118239937A (zh) | 2017-08-09 | 2024-06-25 | 戴纳立制药公司 | 化合物、组合物及方法 |
| SI4154882T1 (sl) * | 2017-08-14 | 2026-01-30 | Prilenia Neurotherapeutics Ltd. | Zdravljenje amiotrofične lateralne skleroze s pridopidinom |
| DK3676297T3 (da) | 2017-09-01 | 2023-08-14 | Denali Therapeutics Inc | Forbindelser, sammensætninger og fremgangsmåder |
| EP3704096B1 (en) | 2017-11-02 | 2026-04-22 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| CA3080804A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704125B1 (en) | 2017-11-02 | 2026-03-11 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704098B1 (en) | 2017-11-02 | 2024-01-24 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| CN108517001A (zh) | 2018-05-17 | 2018-09-11 | 江苏恩华络康药物研发有限公司 | 水溶性别孕烯醇酮衍生物及其用途 |
| JP2021529814A (ja) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| TWI877863B (zh) | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| MX2021013197A (es) | 2019-04-30 | 2022-02-24 | Calico Life Sciences Llc | Cicloalquilos sustituidos como moduladores de la vía integrada del estrés. |
| AR118836A1 (es) | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía de tensión integrada |
-
2019
- 2019-10-09 TW TW112140853A patent/TWI877863B/zh active
- 2019-10-09 TW TW108136745A patent/TWI771621B/zh active
- 2019-10-09 TW TW114105524A patent/TW202545902A/zh unknown
- 2019-10-09 TW TW111122712A patent/TWI832295B/zh active
- 2019-10-11 MY MYPI2021001892A patent/MY207223A/en unknown
- 2019-10-11 PT PT197954134T patent/PT3864003T/pt unknown
- 2019-10-11 KR KR1020227038367A patent/KR20220151232A/ko not_active Ceased
- 2019-10-11 ES ES19795413T patent/ES2938061T3/es active Active
- 2019-10-11 MD MDE20210768T patent/MD3864003T2/ro unknown
- 2019-10-11 SI SI201930432T patent/SI3864003T1/sl unknown
- 2019-10-11 JP JP2021519747A patent/JP7203964B2/ja active Active
- 2019-10-11 RS RS20230160A patent/RS64013B1/sr unknown
- 2019-10-11 AR ARP190102911A patent/AR116693A1/es not_active Application Discontinuation
- 2019-10-11 EP EP19795413.4A patent/EP3864003B1/en active Active
- 2019-10-11 WO PCT/US2019/055850 patent/WO2020077217A1/en not_active Ceased
- 2019-10-11 PE PE2023001965A patent/PE20241068A1/es unknown
- 2019-10-11 EP EP22210424.2A patent/EP4209483B1/en active Active
- 2019-10-11 IL IL300799A patent/IL300799B2/en unknown
- 2019-10-11 UY UY0001038415A patent/UY38415A/es not_active Application Discontinuation
- 2019-10-11 CA CA3115668A patent/CA3115668A1/en active Pending
- 2019-10-11 FI FIEP19795413.4T patent/FI3864003T3/fi active
- 2019-10-11 SG SG11202103531YA patent/SG11202103531YA/en unknown
- 2019-10-11 SM SM20230058T patent/SMT202300058T1/it unknown
- 2019-10-11 KR KR1020217013975A patent/KR102464077B1/ko active Active
- 2019-10-11 DK DK19795413.4T patent/DK3864003T3/da active
- 2019-10-11 CR CR20230182A patent/CR20230182A/es unknown
- 2019-10-11 AU AU2019356565A patent/AU2019356565B2/en active Active
- 2019-10-11 IL IL321549A patent/IL321549A/en unknown
- 2019-10-11 IL IL282153A patent/IL282153B2/en unknown
- 2019-10-11 PE PE2021000488A patent/PE20211277A1/es unknown
- 2019-10-11 PL PL19795413.4T patent/PL3864003T3/pl unknown
- 2019-10-11 MX MX2021004163A patent/MX2021004163A/es unknown
- 2019-10-11 CN CN202211415030.XA patent/CN116283647A/zh active Pending
- 2019-10-11 CN CN201980080430.XA patent/CN113423685B/zh active Active
- 2019-10-11 LT LTEPPCT/US2019/055850T patent/LT3864003T/lt unknown
- 2019-10-11 HU HUE19795413A patent/HUE061297T2/hu unknown
- 2019-10-11 EP EP25219299.2A patent/EP4714961A2/en active Pending
- 2019-10-11 MA MA53861A patent/MA53861B1/fr unknown
- 2019-10-11 KR KR1020257034351A patent/KR20250153325A/ko active Pending
- 2019-10-11 HR HRP20230222TT patent/HRP20230222T1/hr unknown
-
2021
- 2021-04-08 PH PH12021550786A patent/PH12021550786A1/en unknown
- 2021-04-09 CL CL2021000875A patent/CL2021000875A1/es unknown
- 2021-04-09 MX MX2023009561A patent/MX2023009561A/es unknown
- 2021-04-09 US US17/227,071 patent/US11149043B2/en active Active
- 2021-04-09 DO DO2021000064A patent/DOP2021000064A/es unknown
- 2021-05-10 EC ECSENADI202132861A patent/ECSP21032861A/es unknown
- 2021-05-11 CO CONC2021/0006098A patent/CO2021006098A2/es unknown
- 2021-09-02 US US17/446,807 patent/US20220251123A1/en active Pending
-
2022
- 2022-04-07 AR ARP220100871A patent/AR125309A2/es unknown
- 2022-12-27 JP JP2022209518A patent/JP2023040106A/ja active Pending
-
2024
- 2024-01-02 AU AU2024200013A patent/AU2024200013B2/en active Active
-
2025
- 2025-02-25 JP JP2025027546A patent/JP2025081607A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022504638A5 (https=) | ||
| JP2022530647A5 (https=) | ||
| RU2020117900A (ru) | Модуляторы интегрированного стресса | |
| RU2020117927A (ru) | Модуляторы интегрированного стресса | |
| JP2021501789A5 (https=) | ||
| JP2021501790A5 (https=) | ||
| JP2021501779A5 (https=) | ||
| JP2021501786A5 (https=) | ||
| JP2021501781A5 (https=) | ||
| JP2021501787A5 (https=) | ||
| JP2021501780A5 (https=) | ||
| JP2021501785A5 (https=) | ||
| JP2025504859A5 (https=) | ||
| RU2765737C2 (ru) | Способ лечения фокально-сегментарного гломерулосклероза | |
| JP2013502431A5 (https=) | ||
| CA2980395A1 (en) | Heterocyclic compounds and their use in preventing or treating bacterial infections | |
| JP2017537886A5 (https=) | ||
| JP2010535211A (ja) | 炎症性障害、脱髄障害および癌を治療するためのインダゾール化合物 | |
| US20240042046A1 (en) | Methods and compounds for modulating huntington's disease | |
| US12612392B2 (en) | Compound, pharmaceutical compositions containing same, synthesis method therefor and use thereof | |
| CA2569112C (en) | Carbapenem antibacterials with gram-negative activity and processes for their preparation | |
| EP2265350A1 (fr) | Procede de preparation de cristaux a base d'un ester d'acide gras | |
| RU2021112336A (ru) | Пролекарственные модуляторы интегрированного пути стресса | |
| RU2024122038A (ru) | Пролекарственные модуляторы интегрированного пути стресса | |
| US20260035355A1 (en) | Compound, pharmaceutical composition comprising same, and use thereof |